Description
Anti-Integrin α5β1 Antibody, Non-Fucosylated (BioBet-1113ZP) is a human monoclonal IgG antibody against Integrin α5β1. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer; Solid Tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Integrin α5β1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Integrin α5β1
Full Name
Integrin alphaV beta1
Background
This is a heterodimer. Its α5 subunit is 36% identical to the GPIIb subunit. This complex is located mainly on endothelial cells but also on smooth muscle cells, macrophages and platelets. Its main function is in the adhesion of cells to the extracellular matrix components.
Alternative Names
Integrin α5β1; GPV/IIIa; GPV/IIa
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with ITGA5 include Colorectal Cancer, Hereditary Nonpolyposis, Type 8 and Lung Cancer.
Related Pathways
Its related pathways are Integrin Pathway and Degradation of the extracellular matrix.
Function
Integrin alpha-5/beta-1 (ITGA5:ITGB1) is a receptor for fibronectin and fibrinogen. It recognizes the R-G-D sequence in the ligand. ITGA5: ITGB1 binds to PLA2G2A through a site (site 2) different from the classical ligand binding site (site 1), thereby inducing a change in the conformation of the integrin and enhancing the binding of the ligand to site 1. ITGA5: ITGB1 acts as a receptor for fibrillin 1 (FBN1) and mediates r-g-d-dependent cell adhesion to FBN1. ITGA5: ITGB1 is a receptor for IL1B, and its binding is essential for IL1B signaling. ITGA5: ITGB3 is the receptor for soluble CD40LG and is required for the CD40/CD40LG signaling pathway. (Microbial infection) Integrin ITGA5: ITGB1 acts as a receptor for human metapneumovirus. (Microbial infection) Integrin ITGA2: ITGB1 acts as a receptor for human parvovirus B19. (Microbial infection) In the case of HIV-1 infection, the interaction with the extracellular virus Tat protein seems to enhance the angiogenesis of Kaposi's sarcoma lesions.
Post-translational modifications
Proteolytic cleavage by PCSK5 mediates activation of the precursor.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1113ZP
Description
This is a fully human, fragment crystalizable (Fc)-engineered IgG1 mAb, which specifically neutralizes α5 and binds the Fcγ receptors (FcγR) with enhanced affinity. In vitro, PF-5412 potently inhibited α5β1-mediated intracellular signaling, cell adhesion, migration, and endothelial cell (EC) tubulogenesis. The dual mechanism of action and robust antitumor efficacy of PF-5412 support its clinical development for the treatment of a broad spectrum of human malignancies.
Antibody Indication
Cancer; Solid Tumors
